HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
about
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literatureA whole-genome sequence and transcriptome perspective on HER2-positive breast cancersHigh HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya.HER2-positive breast cancer is lost in translation: time for patient-centered research.Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up.[Molecular classification of bladder cancer. Possible similarities to breast cancer].Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.
P2860
Q33680890-BFFD228A-9813-45C6-8DB3-3A487A2E3EFCQ35343184-6CE1BB5D-2C79-4445-95AD-B826F2F61569Q36107363-B9AE7339-334C-458E-8321-E0DF4BA76E41Q36413297-F1EFA3AE-B3DE-4B2E-AD56-4B5A1704D88BQ36825817-582EE4E7-206C-4797-9EC9-C11AFD7E74E7Q37099507-AE99EE16-CEFE-423F-924E-0A5C479D512BQ37142882-4F54503D-2C6D-40E3-865B-8D373759D533Q37301435-6066A60E-648F-4D6F-8138-CF4459B05313Q38326102-2D02AFA9-EC19-44BE-B259-44DBA3121700Q38387030-F498103C-7AEA-4750-BE14-17DC1C90F15DQ38644673-E624C0A0-1560-4CB8-AF5C-D841C8540CD6Q38648765-BF43C46A-4190-4E9C-83B9-38D4A2C55695Q39263199-37E3EE33-F70B-4447-B1DD-7D8BA228AA1DQ41443052-CCAB1229-84D9-4C95-93AD-BF4AD69EA1A8Q42316809-028409DE-A206-44DA-BA1D-B4D3C964B42DQ43825401-3694C53F-3BC0-4C88-8E52-CBBFCBEC5745Q47260496-288518BB-BCAC-44E0-9B9B-C9A8AACD8B9BQ48102534-CB0C15F2-4433-4C0D-AEF6-1666C2123240Q48219547-A9EC7210-FF93-4687-9CFC-3CB51DA97326Q50562601-F629FAC1-5F3F-45F2-9414-C9FFFD398153Q53205542-8ADB7726-08CC-496C-8B98-31D8CD696299Q54324226-76BFFE2B-1D04-4DD1-A6BD-842EF4CFCA5A
P2860
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
HER2 and ESR1 mRNA expression ...... nts with primary breast cancer
@en
type
label
HER2 and ESR1 mRNA expression ...... nts with primary breast cancer
@en
prefLabel
HER2 and ESR1 mRNA expression ...... nts with primary breast cancer
@en
P2093
P2860
P50
P356
P1476
HER2 and ESR1 mRNA expression ...... nts with primary breast cancer
@en
P2093
Bruno V Sinn
Carsten Denkert
Christine Solbach
Hans Tesch
Jan C Brase
Judith Prinzler
Keyur Mehta
Knut Engels
Ralf Kronenwett
P2860
P2888
P356
10.1186/BCR3384
P50
P577
2013-02-07T00:00:00Z
P5875
P6179
1033376014